Efficacy and safety of low-dose imatinib in an elderly patient with
mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1
Optimal treatment for Philadelphia chromosome-positive mixed phenotype
acute leukemia (Ph+ MPAL), particularly in elderly patients with
comorbidities, has not been established. We present the elderly Ph+ MPAL
case who discontinued initial treatment with dasatinib and whose disease
was successfully controlled by low-dose imatinib with monitoring of drug
concentrations in blood.